[Remission in pediatric rheumatology]

Area of Science:

• Pediatric Rheumatology
• Immunology
• Pharmacology

Background:

• Advancements in defining disease activity, improvement, and deterioration in juvenile idiopathic arthritis (JIA).
• Establishment of international research collaborations enabling controlled studies of new biological therapies.
• Increasing achievement of inactive disease states in polyarticular JIA patients, highlighting the need for remission criteria.

Purpose of the Study:

• To evaluate the effectiveness of new biologicals in patients with juvenile idiopathic arthritis (JIA).
• To assess the achievement of inactive disease and remission in JIA patients treated with new therapies.
• To examine the prognostic value of current remission criteria and the potential for biomarkers or imaging to enhance them.

Main Methods:

• Controlled studies involving patients with juvenile idiopathic arthritis (JIA).
• Application of the Wallace criteria for defining inactive disease and remission.
• Analysis of disease persistence after drug cessation and gene expression patterns in patients in remission.

Main Results:

• New biologicals have demonstrated effectiveness in treating JIA, with more patients achieving inactive disease.
• The Wallace criteria are widely used but do not correlate with patient prognosis.
• Despite clinical improvement, many JIA patients experience disease recurrence upon drug withdrawal, and gene expression remains abnormal.

Conclusions:

• While new biological therapies significantly improve JIA management and inactive disease rates, they do not offer a cure.
• Current clinical criteria for remission lack prognostic value, and biomarkers/imaging have not yet improved JIA assessment.
• Further research is needed to understand the underlying pathology and achieve complete disease eradication in JIA.